Toripalimab: 8 agencies, 2024–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused toripalimab: all 7 decisive outcomes across 5 agencies were positive or positive with restrictions.
Every record falls within a 1.7-year window, 11 Dec 2024 to 10 Aug 2026 — a compressed review cycle.
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand), AWMSG (Wales) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for toripalimab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 11 of 11 records date from 2023 or later.
Against its own class, toripalimab is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
1 of these 11 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
NICE (England) was first to assess toripalimab, on 11 Dec 2024; AIFA (Italy) did not open a file until 10 Aug 2026 — a moderate spread of 1.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 11 dated records fall in 2026 alone.
3 of the 8 agencies here assessed toripalimab more than once, G-BA (Germany) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for toripalimab.
The full ledger for toripalimab reads 7 recommended, 3 no benefit and 1 terminated.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 2 Jul 2026 | Loqtorzi — benefit assessment §35a | added benefit: not proven | source |
| DMC (Denmark) | 1 Jun 2026 | Førstelinjebehandling af voksne patienter med inoperabel, fremskreden, recidiverende eller metastatisk øsofagealt planoc… | Anbefalet | source |
| HAS (France) | 1 Apr 2026 | Listing (Transparency Committee) | SMR substantial · ASMR III | source |
| CIPM (Spain) | 25 Mar 2026 | Indicaciones terapéuticas autorizadas: LOQTORZI, en combinación con cisplatino y gemcitabina, está indicado en el tratam… | financed by the SNS · art. 92 a, c, e | source |
| NYE METODER (Norway) | 18 Jan 2026 | I kombinasjon med cisplatin og paklitaksel som førstelinjebehandling hos voksne pasienter med øsofagus plateepitelkarsin… | introduced | source |
6 further decisions for toripalimab, across 6 agencies, are not shown here. They include the most recent record on file, 10 Aug 2026 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 6 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 11 decisions for toripalimab from 8 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.